Moreover, based on the metabolic benefits demonstrated for GLP-1/glucagon and GLP-1/GIP coagonists (“twincretins”), triagonists targeting all 3 incretin receptors have been systematically developed with even stronger efficacy compared to twincretins on weight loss and obesity-related traits, such as reducing liver fat (114, 115). Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.